Siga Technologies Q2 Earnings Call Highlights

Siga Technologies NASDAQ: SIGA reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of its government-focused procurement business after minimal product revenue in the first quarter.

MarketBeat • Aug 7, 2026

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

GlobeNewsWire • Jul 30, 2026

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

Siga Technologies, Inc. remains a Hold, as revenue visibility hinges on BARDA contract renewal, with shares down ~40% since April. SIGA's sole commercial product, TPOXX, faces shrinking opportunities after losing EU approval for MPOX although mgmt is developing pediatric and PEP versions. Q1 2026 results showed stagnant revenues, widening losses, and reliance on a $26m BARDA delivery and $13m Asia Pacific contract.

Seeking Alpha • Jul 28, 2026

Siga Technologies Q1 Earnings Call Highlights

Siga Technologies NASDAQ: SIGA reported a first-quarter loss as product deliveries remained minimal, but management said it expects a pickup in the second quarter tied to an international order and additional deliveries to the U.S. Strategic National Stockpile.

MarketBeat • May 9, 2026

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2026.

GlobeNewsWire • May 7, 2026

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

GlobeNewsWire • Apr 30, 2026

Why Are Siga Technologies Shares Trading Higher?

Siga's board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the special dividend declared last April.

Benzinga • Mar 27, 2026

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the level of the special dividend declared in April 2025. The dividend is payable on April 23, 2026, to shareholders of record at the close of business on April 7, 2026.

GlobeNewsWire • Mar 26, 2026